Moreover, in approximately 50% of cancers especially those fueled by MYC, Hsp90 acts as a nucleating site to form functionally integrated complexes termed ‘epichaperome’, which render tumor cells more sensitive to Hsp90 inhibitors (Hsp90i) (17). This evidence concerns the gene HSP90AA1 and cancer.